Ann: Immutep reports positive TACTI-002 data, page-85

Howdy macca, good fun this mate.....All Aipac related.
Coupla things.......production facilities upgrade, 10 fold why?
maybe, potential applicant (licence buyer) wants guaranteed production before committing...
my thoughts, Immutep want to control production but leave the marketing to potential out licensees...

EMA interest and bridging trial announcement, why? I suggest Immutep have ideas of outlicencing
Aipac for Europe but retain USA/FDA jurisdication, maybe for themselves or for another
license for say, maybe the Americas...

Goetz, when forming a report as a client of Immutep just released, mentioned it in header
paragraph.....Goetz in my view have an uncanny ability to foreshadow later occurences....

note: I don't take any notice of target prices, the market works that out...